Researchers can study vital scientific and genetic insights using the ReproSeq PGT-A Kit. Credit: Thermo Fisher Scientific/Business Wire.

Thermo Fisher Scientific has introduced two new research use reproductive health assays, the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit, for accelerating research on fertility.

Designed to run on the Ion Torrent Genexus Integrated Sequencer, the next-generation sequencing-based assays have been developed to support preimplantation genetic testing-aneuploidy (PGT-A) used to inform intracytoplasmic sperm injection (ICSI) and in vitro fertilisation (IVF) research.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

PGT-A testing helps detect chromosomal abnormalities in samples of embryo and is used in IVF and ICSI research to advance future fertility care options.

Researchers can utilise the ReproSeq PGT-A Kit for studying crucial scientific and genetic insights, which are expected to increase the probability of success for future pregnancies and enhance the health of future generations.

Furthermore, they can access additional quality control features when the ReproSeq PGT-A Kit is used together with the optional Ion AmpliSeq Polyploidy Panel kit.

See Also:

These features enable the detection of contamination, prevention of sample mix-ups and the identification of triploidy in embryos.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thermo Fisher Scientific clinical next-generation sequencing and oncology president Garret Hampton said: “Building on Thermo Fisher’s existing reproductive health offerings, today’s launch brings the benefits of next-generation sequencing to more research labs with the potential of rapid, in-house testing and analysis.

“Considering the far-reaching implications for those struggling with infertility, researchers must have reliable and accurate testing available to advance the fertility field and ultimately improve reproductive health for all.”

Prior to this, Thermo Fisher launched the scalable Diomni Enterprise Software for molecular diagnostics labs and test developers.